Bruker (BRKR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-14
$52.66-1.44%
Close 2026-09-14 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-14
Research Workspace
Put BRKR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve FY2026 non-GAAP EPS of $2.10 to $2.15: FY26 EPS guidance $2.10-$2.15 vs $2.10 target.
View ThesisRevenue growth is slowing — up about 2% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskBruker must maintain its FY2026 revenue guidance of $3.54 to $3.57 billion to justify its current valuation. Revenue grew 5% year over year, and the latest quarter beat expectations. It trades at 29× P/E versus a peer median of 28×, indicating modest expectations compared to our view. The primary risk is the potential for a guidance cut, with a 22% probability of a miss in the next quarter. Peer multiples imply a price about 3% above where it trades (it looks cheap on this basis). The thesis has broken due to the primary pillar being compromised.
Trailing returns as of 2026-09-14. BRKR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering BRKR (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for BRKR in the last 4 months.
Continue this research
Compare BRKR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BRKR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put BRKR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain FY2026 revenue guidance of $3.54 to $3.57 billion
Accelerated bookings support revenue growth guidance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $52.66
The last 12 months of price, then the range of analyst 12-month targets from today’s $52.66.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Drive significant operating margin expansion and profitability
Goodwill impairment indicates potential margin pressures.
Q2 results and guidance suggest potential revenue shortfall.
Advances: Maintain FY2026 non-GAAP EPS guidance of $2.10 to $2.15
Cost reduction signals commitment to EPS guidance.
Threatens: Maintain FY2026 revenue guidance of $3.54 to $3.57 billion
Revenue miss raises concerns about growth trajectory.
Advances: Maintain FY2026 revenue guidance of $3.54 to $3.57 billion
Growth pivot indicates potential for revenue increase.
Indicates growth concerns impacting revenue expectations.
End market growth supports revenue guidance.
